Moderna (NASDAQ:MRNA) Trading Down 1.4% on Insider Selling

Moderna, Inc. (NASDAQ:MRNAGet Rating)’s stock price was down 1.4% on Friday following insider selling activity. The stock traded as low as $138.10 and last traded at $139.36. Approximately 31,664 shares were traded during trading, a decline of 99% from the average daily volume of 4,271,646 shares. The stock had previously closed at $141.28.

Specifically, CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction on Wednesday, June 22nd. The stock was sold at an average price of $136.58, for a total transaction of $5,463,200.00. Following the sale, the chief executive officer now directly owns 5,411,946 shares in the company, valued at approximately $739,163,584.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO David W. Meline sold 164 shares of Moderna stock in a transaction on Wednesday, August 10th. The stock was sold at an average price of $173.66, for a total transaction of $28,480.24. Following the sale, the chief financial officer now directly owns 2,857 shares in the company, valued at approximately $496,146.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction on Wednesday, June 22nd. The stock was sold at an average price of $136.58, for a total value of $5,463,200.00. Following the sale, the chief executive officer now owns 5,411,946 shares in the company, valued at $739,163,584.68. The disclosure for this sale can be found here. In the last three months, insiders have sold 608,048 shares of company stock worth $96,021,642. Corporate insiders own 17.30% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on MRNA. SVB Leerink lifted their price objective on Moderna from $70.00 to $77.00 and gave the stock an “underperform” rating in a report on Monday, August 1st. Morgan Stanley decreased their price objective on Moderna from $199.00 to $197.00 and set an “equal weight” rating for the company in a report on Thursday, August 4th. Deutsche Bank Aktiengesellschaft raised Moderna from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $155.00 to $165.00 in a report on Wednesday. Finally, Piper Sandler decreased their price objective on Moderna from $348.00 to $214.00 and set an “overweight” rating for the company in a report on Tuesday, May 17th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Moderna presently has an average rating of “Hold” and a consensus price target of $227.75.

Moderna Stock Up 0.7 %

The company has a current ratio of 1.99, a quick ratio of 1.71 and a debt-to-equity ratio of 0.04. The firm has a market cap of $56.59 billion, a PE ratio of 4.34, a price-to-earnings-growth ratio of 0.82 and a beta of 1.69. The stock has a fifty day simple moving average of $158.67 and a two-hundred day simple moving average of $151.61.

Moderna (NASDAQ:MRNAGet Rating) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported $5.24 EPS for the quarter, topping the consensus estimate of $4.73 by $0.51. Moderna had a return on equity of 94.76% and a net margin of 61.12%. The company had revenue of $4.73 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same quarter in the previous year, the firm earned $6.46 earnings per share. Moderna’s revenue was up 8.7% on a year-over-year basis. As a group, sell-side analysts expect that Moderna, Inc. will post 26.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Allworth Financial LP grew its holdings in shares of Moderna by 3.5% during the second quarter. Allworth Financial LP now owns 1,780 shares of the company’s stock worth $254,000 after purchasing an additional 60 shares in the last quarter. Parkside Financial Bank & Trust lifted its position in Moderna by 20.1% in the 2nd quarter. Parkside Financial Bank & Trust now owns 371 shares of the company’s stock worth $53,000 after buying an additional 62 shares during the last quarter. Brown Brothers Harriman & Co. lifted its position in Moderna by 3.8% in the 2nd quarter. Brown Brothers Harriman & Co. now owns 1,772 shares of the company’s stock worth $253,000 after buying an additional 65 shares during the last quarter. PFG Private Wealth Management LLC lifted its position in Moderna by 4.5% in the 2nd quarter. PFG Private Wealth Management LLC now owns 1,547 shares of the company’s stock worth $221,000 after buying an additional 66 shares during the last quarter. Finally, American National Bank lifted its position in Moderna by 53.1% in the 1st quarter. American National Bank now owns 199 shares of the company’s stock worth $34,000 after buying an additional 69 shares during the last quarter. Hedge funds and other institutional investors own 60.76% of the company’s stock.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Recommended Stories

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.